Subscribe via RSS
RSS for posts
RSS for comments
Russian research of tumor angiogenesis mechanisms conducted by Skolkovo’s resident OncoMax won the First...
OncoMax presented its research results at the 5th European Multidisciplinary Meeting on Urological Cancers (EMUC) which was held in Marseille, France on 15-17 November 2013. Dr. Ilya Tsimafeyev, Scientific...
OncoMax to present new data of OM-RCA-01 monoclonal anti-FGFR1 antibody at the Education Cancer Meetings
OncoMax, Ltd. (“OncoMax”), a portfolio company of Russia-based Maxwell Biotech Venture Fund founded with the participation of Russian Venture Company announced today that it will be presenting the results...
"OncoMax" has received U.S. patent on drug for targeted therapy of renal cell carcinoma
Biotechnological company OncoMax, Ltd has increased the commercial value of its patent portfolio due to the U.S. patent (US 8487083 July 16, 2013). The document proves originality and innovation of the...
Skolkovo resident OncoMax presented results of its first medicine development OM-RCA-01 at international...
OncoMax presented the results of its research in the field of onco-urologic diseases at the 27th Annual Congress of the European Association of Urologists taking place in Paris during February 24-28. Based...
Ilya Tsimafeyeu, Oncomax' scientific director, about OM-RCA-01
Three portfolio companies of Maxwell Biotech Group will take part in the Russian Cancer Congress
From 13 to 15 November 2012, the World Trade Center, Moscow, will host the XVI Russian Cancer Congress featuring expositions of the largest pharmaceutical and biotechnology companies in the Russian cancer...
Report on OncoMax’s Success in Development of Medicine OM-RCA-01 Sparked Interest at the ASCO Annual...
Preclinical efficacy study results for the first Russian humanised monoclonal antibody OM-RCA-01, indicated for treatment of renal cell carcinoma, were presented at the New Technologies session of the...
Investments in OncoMax were Recognized as the “Transaction of the Year” in the Direct and Venture Capital...
The second annual awarding ceremony of Investor Awards 2012 winners took place on May 23 in Moscow after the end of the forum Invest in Russia. The investment round in the innovative biotechnological company...
OncoMax Presented its Project at the Skolkovo Foundation Board Meeting
The meeting of the Skolkovo Foundation Board with the participation of the President of the Russian Federation Dmitry Medvedev took place in Bauman Moscow State Technical University on April 25. As part...
OncoMax successfully presented at the Annual Congress of the American Association for Cancer Research...
OncoMax, financed by Maxwell Biotech Venture Fund, set up with the participation of RVC OJSC and RVC Seed Fund, presented the results of its studies in the sphere of oncology at the Annual Congress of...
Results of Studies Carried Out by OncoMax Were Presented at the International Conference in Paris
OncoMax addressed the 27th Annual Congress of the European Association of Urologists (EAU), that took place in Paris on February 24-28 with the results of its studies in the field of oncolological urological...
OncoMax to Present at International Oncology Conferences
OncoMax, Ltd. (“OncoMax”), a portfolio company of Russia-based Maxwell Biotech Venture Fund founded with the participation of Russian Venture Company announced today that it will be presenting...
Офисы и лаборатории
Skolkovo Institute of Science and Technology
Skolkovo Open University
Customs and Finance Company
Intellectual property centre
© 2020 Skolkovo Foundation